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November 16, 2010:1763–5hem completely is impractical. The NCDR CathPCI Registry
eperfusion measures allow for exclusions for patient-centered reasons
or delay (e.g., the need for a decision-altering diagnostic test prior to
ossible primary percutaneous coronary intervention). Although the
easures may include examples, they do not include specific lists of
hese reasons. Such exclusions were integrated into the measure to
cknowledge the fact that high-quality clinicians providing the best
are will, on occasion, face situations where their delivery of reperfu-
ion therapy is delayed for clinically appropriate reasons. As Ellis and
olleagues point out, the flexibility intrinsic to this exclusion may
reate opportunities for gaming.
Although we believe that the high standards of medical profes-
ionals protect the integrity of the measures to some extent, we are
ot so naive to assume that professional integrity alone will
liminate gaming. Unfortunately, however, addressing this issue by
emoving the exclusion as proposed by Ellis and colleagues raises
ubstantial problems of its own by undermining the clinical face
alidity of the measure. The absence of such exclusions creates
ther compelling arguments—namely, that centers that care for
articularly complex patients, where clinically reasonable delays are
ore common—are disproportionately penalized. Indeed, before
he Department of Health and Human Services’ Centers for
edicare and Medicaid Services/Joint Commission measure in-
orporated this exclusion, such complaints were among the most
ommon causes for objection to the reperfusion measures (Jo
eBuhr, Colorado Foundation for Medical Care, personal
ommunication, July 2010).
This dilemma, among the many complex issues surrounding
easuring reperfusion quality, was addressed explicitly by an
CC/AHA Writing Group comprised of experienced clinicians
nd experts in performance measurement (2). This writing group
oncluded that this exclusion is important, despite its limitations.
his opinion is reflected in the current ACC/AHA performance
easures for acute myocardial infarction (3).
Further, the Writing Group recommended: 1) surveillance for
he proportion of cases where exclusions are noted, including the
istribution of the exclusions by institution; and 2) audit of the
linical appropriateness of exclusions both in a targeted manner
i.e., among institutions with the highest numbers of excluded
ases) as well as randomly.
To this point, NCDR metrics have been used predominantly for
uality improvement. Although some of the metrics reported to
egistry participants are not intended for accountability purposes,
thers—including the time-to–primary percutaneous coronary inter-
ention metric in question—might reasonably be viewed as useful in
his regard. As this occurs, we agree with Ellis and colleagues that
reater scrutiny of exclusions, consistent with the recommendations
y the ACC/AHA Writing Group is warranted.
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erial Intravascular
ltrasound Examinations
nd Clinical Outcome
e read with interest the paper by Nicholls et al. (1) investigating
he relationship between intravascular ultrasound (IVUS)–derived
easures of atherosclerosis (baseline and change in percent ather-
ma volume) and cardiovascular outcomes (death, myocardial
nfarction, and coronary revascularization). Based on the study
esign, however, it seems difficult to determine the relationship
etween change in percent atheroma volume and death or myo-
ardial infarction because IVUS examination at follow-up is often
issing in patients with such clinical events. To clarify this point,
t would be of great help if the investigators would provide data
egarding how many patients died or had myocardial infarction
nd how long patients underwent follow-up for occurrence of
ardiovascular outcomes after follow-up IVUS examination.
In addition, Figure 1 of their paper (1) shows a striking increase
n cardiovascular events between 500 and 600 days (repeat IVUS
xamination period), suggesting angiographically/IVUS-driven re-
ascularization (2). Therefore, it remains unclear whether IVUS-
erived measures of atherosclerosis are associated with clinical
utcomes without routine angiographic/IVUS follow-up.
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